Articles Tagged With: Pharmacology
-
Imetelstat Injection (Rytelo)
The U.S. Food and Drug Administration has approved a first-in-class telomerase inhibitor for the treatment of myelodysplastic syndrome with transfusion-dependent anemia.
-
Cefepime and Enmetazobactam Injection (Exblifep)
The U.S. Food and Drug Administration has approved the combination of cefepime and enmetazobactam (FPE) for the treatment of complicated urinary tract infections (cUTIs).
-
Aprocitentan (Tryvio)
The U.S. Food and Drug Administration (FDA) has approved a first-in-class endothelin receptor antagonist for the treatment of high blood pressure not adequately controlled with other antihypertensives.
-
Momelotinib Tablets (Ojjaara)
Momelotinib can be prescribed to treat intermediate- or high-risk myelofibrosis.
-
Major Cardiovascular Event Risk Reduction with Pitavastatin in Patients Living with HIV
Among participants living with HIV who are at low-to-moderate risk for cardiovascular disease, those who received pitavastatin were 35% less likely to experience a major adverse cardiovascular event over a follow-up of approximately five years vs. those who received placebo.
-
The Hemodynamic Effects of an SGLT2 Inhibitor in Heart Failure with Preserved Ejection Fraction
The authors of a small, placebo-controlled study of 24 weeks of dapagliflozin therapy in patients with heart failure with preserved ejection fraction reported reductions in pulmonary capillary wedge pressure, which may explain the reductions in heart failure hospitalizations or cardiovascular death in larger randomized outcome trials.
-
Canakinumab Injection (Ilaris)
Canakinumab can be prescribed to adults with gout in whom nonsteroidal anti-inflammatory drugs and colchicine are contraindicated, are not tolerated, or do not provide an adequate response, and in whom repeated courses of corticosteroids are not appropriate.
-
Glyceryl Trinitrate Topical Gel (Eroxon)
Eroxon can be recommended to treat adult men (age 18 years and older) with erectile dysfunction.
-
Is the Combination of a GLP-1 Agonist and a SGLT2 Inhibitor Safe?
Adding a GLP-1 RA in a subgroup of type 2 diabetes patients on baseline SGLT2 inhibitor therapy revealed GLP-1 RA reduces major adverse cardiovascular event rates, regardless of baseline SGLT2 use.
-
The Hemodynamic Effects of an SGLT2 Inhibitor in Heart Failure with Preserved Ejection Fraction
The authors of a small, placebo-controlled study of 24 weeks of dapagliflozin therapy in patients with heart failure with preserved ejection fraction reported reductions in pulmonary capillary wedge pressure, which may explain the reductions in heart failure hospitalizations or cardiovascular death in larger randomized outcome trials.